Recombinant Human IL-6
- Brand BD Pharmingen™
- Concentration 200 µg/ml
- Reactivity Human (QC Testing)
ELISA Standard (Routinely Tested)
Blocking, Bioassay (Tested During Development)
- Storage Buffer Frozen aqueous buffered solution containing BSA and glycerol.
- Regulatory Status RUO
Regulatory Status Legend
Interleukin-6 (IL-6) is a potent lymphoid cell growth factor which affects B lymphocytes, T lymphocytes, and hybridoma cells. It will also affect cytotoxic T cells in combination with other factors, such as IL-2 and interferon-γ. Human IL-6 is a 20.5 kD protein containing 184 amino acid residues. Recombinant human IL-6 (Cat. No. 550071) is supplied as a frozen liquid comprised of 0.22 µm filtered aqueous buffered solution, glycerol and bovine serum albumin, with no preservatives. Recombinant human IL-6 is ≥ 95% pure as determined by SDS-PAGE, and an absorbance assay based on the Beers-Lambert law. The endotoxin level is ≤0.1 ng per µg of human IL-6, as measured in a chromogenic LAL assay.
Suggested Companion Products
Preparation and Storage
Store product at -80°C prior to use or for long term storage of stock solutions.
Rapidly thaw and quick-spin product prior to use.
Avoid multiple freeze-thaws of product.
This preparation contains no preservatives, thus it should be handled under aseptic conditions.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
Upon initial thawing, recombinant human IL-6 (Cat. No. 550071) should be aliquoted into polypropylene microtubes and frozen at -80°C for future use. Alternatively, the product can be diluted in sterile neutral buffer containing not less than 0.5 - 10 mg/mL carrier protein, such as human or bovine albumin, aliquoted and stored at -80°C. For in vitro biological assay use, carrier protein concentrations of 0.5 - 1.0 mg/mL are recommended. For use as an ELISA standard, carrier protein concentrations of 5 - 10 mg/mL are recommended. Failure to add carrier protein or store at indicated temperatures may result in a loss of activity. Carrier proteins should be pre-screened for possible effects in each investigator's experimental system. Carrier proteins may have an undesired influence on experimental results due to toxicity, high endotoxin levels or possible blocking activity.
ELISA Standard: Recombinant human IL-6 (Cat. No. 550071) can be useful as a quantitative standard for measuring human IL-6 protein levels using sandwich ELISA with the purified MQ2-13A5 antibody (Cat. No. 554543) as a capture antibody and biotinylated MQ2-39C3 (Cat. No. 554546) as the detection antibody. To obtain linear standard curves, investigators may want to consider using doubling dilutions of recombinant human IL-6 from 2,000 - 15 pg/mL to be included for each ELISA plate. For measuring human IL-6 in serum or plasma, investigators are highly encouraged to use the BD OptEIA™ Human IL-6 ELISA Set (Cat. No. 555220) or the BD OptEIA™ Human IL-6 ELISA Kit II (Cat. No. 550799).
Bioassay: Investigators are advised that the Bioassay application is not routinely tested for this material and are highly encouraged to both titrate this material and include appropriate controls in relevant experiments. An activity range of 0.5-3.0x10^8 units/mg, encompassing an
ED50= 30-200 pg/mL, has previously been reported using TF-1 as indicator cells for proliferation, with a unit defined as the amount of material needed to stimulate a half-maximal response at cytokine saturation.
Blocking: Recombinant human IL-6 (Cat. No. 550071) can be useful as a blocking control for flow cytometric analysis when used with FITC- or PE-conjugated MQ2-13A5 antibodies (Cat. No. 554544 or 554545), or FITC- or PE-conjugated MQ2-6A3 antibodies (Cat. No. 554696 or 554697). Investigators are advised that the blocking application is not routinely tested for this material. Intracellular cytokine staining techniques and the use of blocking controls are described in detail by C. Prussin and D. Metcalfe.